{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:57:15Z","timestamp":1772553435416,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,11]]},"DOI":"10.7759\/cureus.69219","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T19:33:41Z","timestamp":1726083221000},"source":"Crossref","is-referenced-by-count":1,"title":["Pyoderma Gangrenosum in an Ulcerative Colitis Patient on Vedolizumab"],"prefix":"10.7759","author":[{"given":"Sharon I","family":"Choe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreecharita","family":"Nidamanuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Rubenzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.021","article-title":"Pathophysiology of pyoderma gangrenosum (PG): an updated review","volume":"73","author":"Braswell SF","year":"2015","unstructured":"Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015, 73:691-8. 10.1016\/j.jaad.2015.06.021","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum","volume":"177","author":"Wu BC","year":"2017","unstructured":"Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2017, 177:72-83. 10.1111\/bjd.15193","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher M","year":"2018","unstructured":"Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018, 63:825-33. 10.1007\/s10620-018-4971-1","journal-title":"Dig Dis Sci"},{"key":"ref4","article-title":"Vedolizumab-induced de novo extraintestinal manifestations","volume":"16","author":"Diaz LI","year":"2020","unstructured":"Diaz LI, Keihanian T, Schwartz I, Bin Kim S, Calmet F, Alejandra Quintero M, Abreu MT. Vedolizumab-induced de novo extraintestinal manifestations. Gastroenterol Hepatol (N Y). 2020, 16:75-81.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","volume":"24","author":"Dubinsky MC","year":"2018","unstructured":"Dubinsky MC, Cross RK, Sandborn WJ, et al.. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018, 24:1876-82. 10.1093\/ibd\/izy065","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.01.012","article-title":"Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab","volume":"3","author":"Yeh JE","year":"2017","unstructured":"Yeh JE, Tsiaras WG. Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab. JAAD Case Rep. 2017, 3:110-2. 10.1016\/j.jdcr.2017.01.012","journal-title":"JAAD Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21821","article-title":"Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis","volume":"35","author":"Shibuya T","year":"2020","unstructured":"Shibuya T, Haga K, Saeki M, et al.. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis. J Clin Apher. 2020, 35:488-92. 10.1002\/jca.21821","journal-title":"J Clin Apher"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab106","article-title":"Pyoderma gangrenosum in an ulcerative colitis pediatric patient during vedolizumab therapy successfully treated with oral cyclosporine","volume":"27","author":"Graziano F","year":"2021","unstructured":"Graziano F, Macaluso FS, Cassata N, Citrano M, Orlando A. Pyoderma gangrenosum in an ulcerative colitis pediatric patient during vedolizumab therapy successfully treated with oral cyclosporine. Inflamm Bowel Dis. 2021, 27:e110-1. 10.1093\/ibd\/izab106","journal-title":"Inflamm Bowel Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/20406223231194190","article-title":"Pyoderma gangrenosum in ulcerative colitis patient treated with vedolizumab: adsorptive granulocyte\/monocyte apheresis as a new therapeutic option refractory cases - a case report and literature review","volume":"14","author":"Mastronardi M","year":"2023","unstructured":"Mastronardi M, Cavalcanti E, Labarile N, Armentano R, Gabriele F, Curlo M. Pyoderma gangrenosum in ulcerative colitis patient treated with vedolizumab: adsorptive granulocyte\/monocyte apheresis as a new therapeutic option refractory cases - a case report and literature review. Ther Adv Chronic Dis. 2023, 14:10.1177\/20406223231194190","journal-title":"Ther Adv Chronic Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.05.006","article-title":"Circulating integrin alpha4\/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype","volume":"193","author":"Lord JD","year":"2018","unstructured":"Lord JD, Long SA, Shows DM, et al.. Circulating integrin alpha4\/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018, 193:24-32. 10.1016\/j.clim.2018.05.006","journal-title":"Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13670","article-title":"The Treg\/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum","volume":"173","author":"Caproni M","year":"2015","unstructured":"Caproni M, Antiga E, Volpi W, et al.. The Treg\/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol. 2015, 173:275-8. 10.1111\/bjd.13670","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.11.007","article-title":"Tissue and peripheral eosinophilia as predictors for disease outcome in children with ulcerative colitis","volume":"49","author":"Morgenstern S","year":"2017","unstructured":"Morgenstern S, Brook E, Rinawi F, Shamir R, Assa A. Tissue and peripheral eosinophilia as predictors for disease outcome in children with ulcerative colitis. Dig Liver Dis. 2017, 49:170-4. 10.1016\/j.dld.2016.11.007","journal-title":"Dig Liver Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000905","article-title":"Vedolizumab-associated hypereosinophilia and hepatoxicity","volume":"9","author":"De Marco D","year":"2022","unstructured":"De Marco D, Bessissow T, Marcus V, Benmassaoud A. Vedolizumab-associated hypereosinophilia and hepatoxicity. ACG Case Rep J. 2022, 9:e00905. 10.14309\/crj.0000000000000905","journal-title":"ACG Case Rep J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond J","year":"2023","unstructured":"Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG. Pyoderma gangrenosum: treatment options. Drugs. 2023, 83:1255-67. 10.1007\/s40265-023-01931-3","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295512-pyoderma-gangrenosum-in-an-ulcerative-colitis-patient-on-vedolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T19:33:46Z","timestamp":1726083226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295512-pyoderma-gangrenosum-in-an-ulcerative-colitis-patient-on-vedolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.69219","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}